ferumoxsil

a large superparamagnetic iron oxide colloid; a miscible darkening agent; see also the dextran-coated superparamagnetic iron oxides - ferumoxides and ferumoxtran

Also Known As:

Networked: 5 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Mäkelä, J: 1 article (01/2008)
2.	Mäkinen, M: 1 article (01/2008)
3.	Piippo, U: 1 article (01/2008)
4.	Pääkkö, E: 1 article (01/2008)

Related Diseases

1.	Female Genital Diseases 07/01/1995 - "The purpose of this study was to determine the tolerance and the efficacy of the oral contrast agent ferumoxsil in the assessment of gynecologic diseases. " 07/01/1995 - "Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases."
2.	Neoplasms (Cancer) 02/01/1996 - "In a phase III clinical trial we have determined the safety and efficacy of Lumirem in the assessment of gynecological neoplasms. " 11/01/1997 - "Twenty patients with suspected rectosigmoid and ovarian tumors were prospectively examined before and after rectal administration of 300 to 600 ml of the superparamagnetic contrast agent Ferumoxsil. "
3.	Rectal Neoplasms (Rectal Cancer) 01/01/2008 - "37 consecutive patients with rectal cancer were imaged using a mixture of ferumoxsil and methylcellulose endorectally, and a gadolinium contrast intravenously. "
4.	Polyps 05/01/2008 - "MRC found 1 of 22 (5%) polyps <6 mm, 2 of 3 (67%) polyps 6-10 mm, and 2 of 2 (100%) polyps >10 mm. MRC with fecal tagging using barium sulfate/ferumoxsil as contrast agent will give better overall assessment of the colon wall compared to barium sulfate alone. "

Related Drugs and Biologics

1.	Contrast Media
2.	Methylcellulose (BFL)
3.	Gadolinium
4.	Barium Sulfate (Barite)

Related Therapies and Procedures

1.	Rectal Administration